- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05392699
ABOD2011 em pacientes com tumores sólidos avançados progrediram após terapia sistêmica padrão
Um estudo aberto-cego de escalonamento de dose para avaliar a segurança, a tolerabilidade e a eficácia preliminar do ABOD2011 em pacientes com tumores sólidos avançados que progrediram após a terapia sistêmica padrão
Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection.
The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Beijing, China
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- 18 years and older.
- Understand and voluntarily sign the informed consent form (ICF).
- Histopathologically confirmed recurrent or metastatic solid tumors.
- Failure of prior systemic standard of care, or intolerance to severe toxicity, or lack of standard of care.
- Presence of at least one measurable lesion as assessed by RECIST Version 1.1.
- At least one superficial or deep lesion for intratumoral administration and biopsy.
- Sufficient organ functions.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
- Weight > 30 kg.
- Expected survival longer than 12 weeks.
- Evidence of menopause in female patients, or for women of childbearing potential: negative for urine or blood pregnancy.
Exclusion Criteria:
- Any systemic anti-tumor therapy, within 28 days prior to the first dose.
- Radiotherapy within 14 days prior to first dose.
- Use of immunosuppressants.
- Major surgery within 28 days.
- Inadequately controlled diseases.
- Active autoimmune and inflammatory diseases.
- Clinically symptomatic central nervous system tumors or metastases.
- Toxicity of prior anti-tumor therapy is still NCI-CTCAE ≥ 2.
- Other malignancies within the previous 5 years with the exception of cured basal cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the breast, and carcinoma in situ of the cervix.
- Active infections.
- Other conditions that may increase the risk associated with the study drug, or affect the study compliance, etc., which, in the opinion of the investigator, are not suitable for participation in the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Human single chain IL-12 mRNA-single dose
Human single chain IL-12 mRNA-single dose |
human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only |
|
Experimental: Human single chain IL-12 mRNA-multiple dose
Human single chain IL-12 mRNA-multiple dose |
human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants Experiencing dose-limiting toxicities (DLTs)
Prazo: From first dose to Day 28
|
Number of Participants Experiencing dose-limiting toxicities (DLTs) |
From first dose to Day 28
|
|
Number of Participants Experiencing Adverse Events (AEs)
Prazo: From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
Number of Participants Experiencing Adverse Events (AEs) |
From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
|
Number of Participants Experiencing Severe Adverse Events (SAEs)
Prazo: From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months
|
Number of Participants Experiencing Severe Adverse Events (SAEs) |
From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall Response Rate (ORR)
Prazo: Up to 36 months
|
Overall Response Rate (ORR) |
Up to 36 months
|
|
Disease Control Rate(DCR)
Prazo: Up to 36 months
|
Disease Control Rate(DCR) |
Up to 36 months
|
|
Duration of Response (DOR)
Prazo: Up to 36 months
|
Duration of Response (DOR) |
Up to 36 months
|
|
Progression-Free Survival (PFS)
Prazo: Up to 36 months
|
Progression-Free Survival (PFS) |
Up to 36 months
|
|
Overall Survival
Prazo: Up to 36 months
|
Overall Survival |
Up to 36 months
|
|
Maximum observed concentration (Cmax) of ABOD2011
Prazo: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Maximum observed concentration (Cmax) of ABOD2011 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Area under the concentration-time curve (AUC) of ABOD2011
Prazo: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Area under the concentration-time curve (AUC) of ABOD2011 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Maximum observed concentration (Cmax) of IL-12
Prazo: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Maximum observed concentration (Cmax) of IL-12 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Area under the concentration-time curve (AUC) of IL-12
Prazo: From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Area under the concentration-time curve (AUC) of IL-12 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
|
Plasma concentration of IFN gamma
Prazo: From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Plasma concentration of IFN gamma |
From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Ning Li, Doctor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- ABOD2011-001
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .